Neutral
Vertex Pharmaceuticals dominates the cystic fibrosis market, and this report explores whether its expansion into gene editing and pain management can ...
Bullish
Morgan Stanley has raised its price target for Vertex Pharmaceuticals (VRTX) to $612 from $596, maintaining an Overweight rating. This decision follow...
Bullish
Jim Cramer, host of "Mad Money," recommends buying Vertex Pharmaceuticals. He also provided his views on Oddity Tech, ImmunityBio, Aehr Test Systems, ...
Neutral
Vertex Pharmaceuticals dominates the cystic fibrosis (CF) market, but faces patent expirations in the late 2030s. The company is diversifying its pipe...